Kashiv Pharma, LLC
USPTO PatentsView assignee record - 6 granted patents across 3 technology areas, recorded in grant years 2016–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).
The verdict
According to USPTO PatentsView, Kashiv ranks #41,187 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 3 technology areas.
- #41,187
- of 49,997 US assignees by volume
- 20th percentile
- by Innovation Score (26.3/100)
- 22.3
- avg claims per patent
- -80%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R41187 · US Corporation #41,187 · 6 grants
GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 6 grants
- LOWER-Q #41,187/49,997
- PHOTO-FINISH Kapito
- CPC-NARROW A61K · 3 areas
- INNOV-THIN 26.3/100
- CLAIMS-DENSE 22.3 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -80% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Kapito Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Kashiv’s 26.3 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Kashiv
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Kashiv Pharma · this assignee 26
Kashiv Pharma · this assignee
26 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Kashiv's Innovation Score is 26.3/100 (20th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Kashiv?
Each dot is one of Kashiv’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Kashiv’s own 22.3 claims/patent is ABOVE the 9.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Kashiv's grants concentrate
Kashiv Pharma, LLC is a focused PatentsView assignee: 3 CPC subclasses with 50% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2016 (2 grants) versus a trough of 1 in 2019. By volume, Kashiv sits between Kapito Inc. and Kayrros.
Who files at Kashiv's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Kapito
Kapito Inc.
6 patents
- Kappler Med + Org
Kappler Med + Org GmbH
6 patents
- Kardiolytics
Kardiolytics Inc.
6 patents
- Karltex Machine
Karltex Machine, Inc.
6 patents
- Katayama Kogyo
Katayama Kogyo Co., Ltd.
6 patents
- Katena Products
Katena Products, Inc.
6 patents
- Kawasaki Heavy In…
Kawasaki Heavy Industries, Ltd.
6 patents
- Kayrros
Kayrros
6 patents
- Kashiv Pharma ◀
Kashiv Pharma, LLC
6 patents
What this shows Kashiv holds 6 patents at rank #41,233, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Kashiv
By rank, the assignees closest to #41,233 in granted patent volume.
- Kapito Inc. #41,229 · 6 patents
- Kappler Med + Org GmbH #41,230 · 6 patents
- Kardiolytics Inc. #41,231 · 6 patents
- Karltex Machine, Inc. #41,232 · 6 patents
- Katayama Kogyo Co., Ltd. #41,234 · 6 patents
- Katena Products, Inc. #41,235 · 6 patents
- Kawasaki Heavy Industries, Ltd. #41,236 · 6 patents
- Kayrros #41,237 · 6 patents
Leaders in A61K (Preparations FOR Medical)
Other assignees with the most granted patents in Kashiv's primary technology class.
- The Regents of the University of California 1,779 in class
- L'Oreal 1,250 in class
- Novartis AG 988 in class
- The Procter & Gamble Company 985 in class
- The Board of Regents of the University of Texas System 950 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 813 in class
- The Trustees of the University of Pennsylvania 768 in class
- Merck Sharp & Dohme LLC 760 in class
Kashiv's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
26 20th percentile higher than 20% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 2 | 33.3% |
| 2018 | 2 | 33.3% |
| 2019 | 1 | 16.7% |
| 2021 | 1 | 16.7% |
Which technologies does Kashiv Pharma, LLC patent most?
Top 3 of 3 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Kashiv Pharma, LLC's patent record in context - here's where to go next.
- Kashiv Pharma, LLC's lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 50% of its portfolio - see every assignee active in that class. Explore A61K
- Ranked #41,187 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Kashiv Pharma, LLC against Kapito Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 26.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.